VectorBuilder Founder and Chief Scientist, Dr. Bruce Lahn, Named to Forbes China Top 100 Oversea Chinese Elite
GUANGZHOU, China--(BUSINESS WIRE)--Nov 14, 2024--
VectorBuilder today announced that its founder and chief scientist, Dr. Bruce Lahn, has been named to the prestigious “2024 Forbes China 100 Most Influential Chinese Selection.” This marks the fourth consecutive year Forbes China has published the list, recognizing 100 outstanding Chinese individuals across business and culture/philanthropy. Former recipients include Jenson Huang of NVIDIA. Dr. Bruce Lahn was selected for his significant contributions to the global life sciences industry.
A Harvard graduate with a Ph.D. from MIT, Dr. Lahn brings over three decades of expertise in genetics. His distinguished career includes a tenured professorship at the University of Chicago and research at the Howard Hughes Medical Institute. With over 100 publications in international journals, his groundbreaking work has earned him numerous accolades, including the Changjiang Scholar Award and recognition in the 2024 PharmaVoice 100.
Dr. Lahn's entrepreneurial spirit is equally impressive. In 2014, he founded VectorBuilder, a revolutionary online platform for vector design and ordering that has streamlined research workflows for hundreds of thousands of life science laboratories globally.
VectorBuilder's intelligent and automated system has been cited in over 5,000 scientific publications and serves over 4,500 institutions in 90+ countries, including 90% of the top 100 QS-ranked universities and 90% of the top 30 global pharmaceutical companies.
Further demonstrating his commitment to innovation, Dr. Lahn established the world's first Gene Delivery Research Institute in Guangzhou in late 2023. This institute focuses on basic research and translational applications in gene delivery, addressing critical global technological barriers. In July 2024, VectorBuilder played a pivotal role in securing Orphan Drug Designation (ODD) from the U.S. FDA for Blueprint Biotech's innovative gene therapy drug, LTGT06.
"I am deeply honored to receive this recognition," said Dr. Lahn. "This is not just an individual achievement, but a testament to the hard work and dedication of the entire VectorBuilder team. We are committed to pushing the boundaries of scientific innovation on a global scale, collaborating with leading researchers worldwide to improve human health."
VectorBuilder, under Dr. Lahn's leadership, has grown into a multinational enterprise with subsidiaries and offices across North America, Europe, and Japan. The company's global perspective and commitment to providing top-tier products and services have solidified its position as a leader in the life sciences industry.
About VectorBuilder Inc.
VectorBuilder is a global leader in gene delivery technologies. As a trusted partner in thousands of labs and biotech/pharma companies around the world, VectorBuilder is a one-stop shop for the design, development and optimization of gene delivery solutions from basic research to clinical applications. Its award-winning Vector Design Studio is a transformative innovation that allows researchers to easily design and order custom vectors online, freeing them from the tedious work of cloning and packaging vectors in the lab. The global company boasts high-throughput vector production capacity, vast vector and component inventories, one-on-one CRO solutions that include advanced AAV capsid engineering capabilities and state-of-the-art GMP facilities. With leading R&D and CDMO manufacturing capacity, the VectorBuilder team strives to provide the most effective gene delivery solutions and develop new tools for life sciences research and genetic medicine.
View source version on businesswire.com:https://www.businesswire.com/news/home/20241114881830/en/
CONTACT: Dan Croucher
danielcroucher@vectorbuilder.com
KEYWORD: ILLINOIS CHINA UNITED STATES NORTH AMERICA ASIA PACIFIC
INDUSTRY KEYWORD: SCIENCE OTHER SCIENCE BIOTECHNOLOGY RESEARCH PHARMACEUTICAL HEALTH HEALTH TECHNOLOGY GENETICS
SOURCE: VectorBuilder Inc.
Copyright Business Wire 2024.
